由于berubicin具有延长多形性胶质母细胞瘤患者总生存期的潜力，FDA授予berubicin治疗该复发性疾病的快速通道指定。据CNS Pharmaceuticals AG公司介绍，FDA已经授予berubicin用于治疗复发后的多形性胶质母细胞瘤（GBM）的快速通道指定。最近启动的一项2期研究（NCT04762069），评估了berubicin与洛莫司汀相比，治疗复发性GB...
A current, potentially pivotal trial for patients with recurrent GBM after first-line therapy has completed enrollment in the US and Europe: a total of 252 patients were randomized 2:1 (Berubicin:Lomustine) after failure of prior therapy. All patients had to have certification of progression ...
CNS Pharmaceuticals announced its European manufacturer, BSP Pharmaceuticals S.p.A. (BSP), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered inc...
("CNSP") has licensed Berubicin and initiated a randomized, controlled clinical trial of Berubicin vs. Lomustine in adults with recurrent GBM after first line therapy. The primary endpoint of this study, being conducted in the United States and Europe, is overall survival (OS), with a ...
A pivotal trial for patients with recurrent glioblastoma (GBM) after first-line therapy has finished enrollment with 252 patients in the US and Europe with evidence of efficacy and no impact on cardiac function. METHODS. CNS Pharmaceuticals plans to evaluate Berubicin in patients with Primary CNS...